Effect of Tranexamic Acid in Ruptured Abdominal Aortic Aneurysms
Launched by SASKATCHEWAN HEALTH AUTHORITY - REGINA AREA · Apr 28, 2014
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
The primary purpose of this study is to examine the effectiveness of TXA in reducing clinically significant bleeding in a novel patient population (ruptured AAA). The first phase of this study will involve a small pilot project, consisting of \~25 patients who will be administered TXA during their treatment for a ruptured AAA. We will compare the amount of clinically significant bleeding from a group of patients treated prospectively with TXA to data collected retrospectively over the previous year from a matched control group of patients who were treated for a ruptured AAA but not given TX...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • any patient with a ruptured aortic aneurysm, regardless of sex, age, ethnicity who may or may not be on anticoagulant or anti-platelet medications for comorbid conditions.
- Exclusion Criteria:
- • pregnancy
- • hypersensitivity to Tranexamic Acid (TXA)
- • acquired defective colour vision
- • active intravascular clotting or disseminated intravascular clotting (DIC)
- • subarachnoid hemorrhage
- • thromboembolic disease
- • age \< 18 years of age
- • known clotting disorder
- • patients receiving thrombin
About Saskatchewan Health Authority Regina Area
The Saskatchewan Health Authority - Regina Area is a prominent healthcare organization dedicated to enhancing patient care and advancing medical research through clinical trials. As a leading sponsor, it focuses on innovative therapeutic interventions and health solutions that address the diverse needs of the community. With a commitment to scientific rigor and ethical standards, the Regina Area Health Authority collaborates with healthcare professionals, researchers, and stakeholders to foster an environment of excellence in clinical research. Their efforts aim to improve health outcomes and contribute to the broader field of medical knowledge while prioritizing patient safety and well-being.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Regina, Saskatchewan, Canada
Patients applied
Trial Officials
Jagadish Rao, MD, FRCSC
Principal Investigator
Saskatchewan Health Authority - Regina Area
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials